Hutt, who was retired partner in residence for Covington & Burling, the Washington firm he rejoined after leaving his post as ...

The megablockbuster helped 40% of children reduce BMI below the obesity threshold at 68 weeks, compared with 0% for placebo, ...

What's happening, why it matters and what's next at FDA. This edition covers a one month extension to the deadline which will ...

The second quarter of 2026 showed a reversal from Q1's seasonal softness, with nine of the world's 10 best-selling drugs ...

DEA placed Haisco's newly approved anesthetic Cypsedo (cipepofol) in Schedule IV, the final regulatory hurdle before the ...

The FDA reiterated that it will not accept foreign clinical trial data generated at site where inspections were denied and ...

FDA reaffirms fluoropolymers such as PTFE are safe and irreplaceable in devices, but the reprieve is US-only: an EU REACH ...

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical ...

Another blow for Novo after data monitoring committee sees little hope of success for the anti-inflammation drug ziltivekimab ...

Growth-stage and start-up companies in medical devices and life sciences are looking at debt growth capital with new eyes. A ...

In amendments to the Health Bill, government says it wants to give new powers the UK’s regulator that could allow it to ...

Celltrion has received nods for amended Phase III trial plans for its CT-P51 and CT-P44 proposed biosimilars to Keytruda ...